Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

The World Health Organisation (WHO) released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said.

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by. Presented ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...